Milan - Delayed Quote EUR

Pharmanutra S.p.A. (PHN.MI)

Compare
51.80
-0.70
(-1.33%)
At close: February 7 at 5:35:15 PM GMT+1
Loading Chart for PHN.MI
DELL
  • Previous Close 52.50
  • Open 52.80
  • Bid 53.10 x --
  • Ask 50.10 x --
  • Day's Range 51.20 - 52.80
  • 52 Week Range 44.85 - 63.50
  • Volume 2,656
  • Avg. Volume 4,779
  • Market Cap (intraday) 497.69M
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 30.65
  • EPS (TTM) 1.69
  • Earnings Date --
  • Forward Dividend & Yield 0.85 (1.50%)
  • Ex-Dividend Date May 6, 2024
  • 1y Target Est 84.33

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company's products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. It distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. The company was founded in 2003 and is based in Pisa, Italy.

www.pharmanutra.it

112

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PHN.MI

View More

Performance Overview: PHN.MI

Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

PHN.MI
4.78%
FTSE MIB Index
8.39%

1-Year Return

PHN.MI
13.96%
FTSE MIB Index
19.63%

3-Year Return

PHN.MI
16.81%
FTSE MIB Index
40.74%

5-Year Return

PHN.MI
133.85%
FTSE MIB Index
51.38%

Compare To: PHN.MI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHN.MI

View More

Valuation Measures

As of 2/6/2025
  • Market Cap

    504.42M

  • Enterprise Value

    504.50M

  • Trailing P/E

    31.07

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.45

  • Price/Book (mrq)

    8.56

  • Enterprise Value/Revenue

    4.43

  • Enterprise Value/EBITDA

    16.22

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.47%

  • Return on Assets (ttm)

    14.04%

  • Return on Equity (ttm)

    28.01%

  • Revenue (ttm)

    107.61M

  • Net Income Avi to Common (ttm)

    14.5M

  • Diluted EPS (ttm)

    1.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.81M

  • Total Debt/Equity (mrq)

    49.36%

  • Levered Free Cash Flow (ttm)

    14.48M

Research Analysis: PHN.MI

View More

People Also Watch